Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong Sells 17,307 Shares of Stock

Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong sold 17,307 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $4.11, for a total value of $71,131.77. Following the transaction, the chief financial officer now directly owns 454,420 shares of the company’s stock, valued at approximately $1,867,666.20. This trade represents a 3.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Stephen Furlong also recently made the following trade(s):

• On Wednesday, February 12th, Stephen Furlong sold 10,845 shares of Neuronetics stock. The stock was sold at an average price of $3.83, for a total value of $41,536.35.
• On Monday, February 10th, Stephen Furlong sold 14,836 shares of Neuronetics stock. The stock was sold at an average price of $3.28, for a total value of $48,662.08.

Neuronetics Trading Up 14.7 %

Shares of Neuronetics stock opened at $5.00 on Wednesday. Neuronetics, Inc. has a 12-month low of $0.52 and a 12-month high of $5.07. The stock has a market cap of $151.75 million, a P/E ratio of -4.07 and a beta of 2.17. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90. The business’s 50 day moving average is $2.34 and its 200-day moving average is $1.45.

Institutional Investors Weigh In On Neuronetics

A number of institutional investors and hedge funds have recently made changes to their positions in STIM. Tradewinds LLC. bought a new stake in shares of Neuronetics during the 4th quarter worth approximately $32,000. XTX Topco Ltd bought a new stake in Neuronetics in the 4th quarter valued at $49,000. Landscape Capital Management L.L.C. bought a new stake in Neuronetics in the 3rd quarter valued at $53,000. GSA Capital Partners LLP raised its stake in Neuronetics by 64.5% in the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock valued at $60,000 after acquiring an additional 30,837 shares during the period. Finally, David J Yvars Group raised its stake in Neuronetics by 47.1% in the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock valued at $75,000 after acquiring an additional 14,825 shares during the period. Institutional investors own 53.59% of the company’s stock.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.